SCHEMBL3678657

SCHEMBL3678657

CC1=NN(c2ccccc2)C(=O)/C1=C/c1ccc(O)c(O)c1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.72
L3MBTL1 Q9Y468 8/20 0.72
MAPT P10636 8/20 0.72
MEN1 O00255 7/20 0.72
ALDH1A1 P00352 5/20 0.72
KDM4E B2RXH2 4/20 0.72
GAA P10253 2/20 0.72
POLB P06746 2/20 0.72
TDP1 Q9NUW8 2/20 0.72
RECQL P46063 1/20 0.72
GALK1 P51570 1/20 0.72
BLM P54132 1/20 0.72
KAT8 Q9H7Z6 1/20 0.60
MAPK1 P28482 3/20 0.57
PKM P14618 2/20 0.56
HPGD P15428 2/20 0.56
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
PTGS2 P35354 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3678658 1.00 KMT2A (0.72) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL419547 0.91 KMT2A (0.60) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL445330 0.91 KMT2A (0.60) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL5476898 0.86 KMT2A (0.58) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL5476893 0.86 KMT2A (0.58) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL420808 0.85 KMT2A (0.76) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL446478 0.85 KMT2A (0.76) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL28473982 0.84 KMT2A (0.82) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL29010258 0.84 KMT2A (0.82) KMT2AL3MBTL1MAPTMEN1ALDH1A1
SCHEMBL16788880 0.84 KMT2A (0.82) KMT2AL3MBTL1MAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4425628-B2 2010-03-03 JP claimed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP claimed
JP-2005505519-A 2005-02-24 JP claimed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP claimed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US claimed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO claimed
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 US disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885MAPT 2548/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885MAPT 2548/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885MAPT 2548/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 KMT2A 4665/4885L3MBTL1 3011/4885MAPT 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.